Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest BioSpecifics Technologies Corp. Stories

2011-05-04 15:30:00

LYNBROOK, N.Y., May 4, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products, announced today that it will host a conference call and live audio webcast at 4:30pm EDT on Tuesday, May 10, 2011 to report its first quarter 2011 financial results and recent corporate highlights. The Company will be hosting a conference call to discuss these financial results and provide a corporate update. In order...

2011-04-13 15:15:00

LYNBROOK, N.Y., April 13, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present at the upcoming BioCentury Future Leaders in the Biotech Industry Conference on Friday, April 15th, 2011, at 3:00 p.m. EDT at the Millennium Broadway Hotel in New York City. A live webcast of the presentation can be accessed under "Calendar of...

2011-04-11 15:05:00

LYNBROOK, N.Y., April 11, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that it will receive a $2.5 million milestone payment as a result of the European launch and first commercial sale of XIAPEX (collagenase clostridium histolyticum ) in the United Kingdom, a major European market. Pfizer, Inc. (Pfizer), the EU licensee received approval from the European Medicines...

2011-03-11 06:00:00

LYNBROOK, N.Y., March 11, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC; the "Company"), a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the fourth quarter and full year ended December 31, 2010. "2010 was an exciting year for the Company, but we are even more excited about 2011 as we look forward to sales growth of XIAFLEX® in the U.S., as well as Pfizer's launch of...

2011-03-10 15:15:00

LYNBROOK, N.Y., March 10, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference on Monday, March 14, 2011, at 11:30 a.m. Pacific Time at the Ritz Carlton in Laguna Niguel, California. A live webcast of the presentation can be accessed under "Calendar of...

2011-03-08 15:30:00

LYNBROOK, N.Y., March 8, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, announced today that it will host a conference call and live audio webcast at 8:30 am ET on March 11, 2011 to report its fourth quarter and full year 2010 financial results and corporate highlights. To participate in the conference call, please dial 800-860-2442 (domestic) or 412-858-4600 (international). The...

2011-03-03 15:54:00

LYNBROOK, N.Y., March 3, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present at the upcoming Cowen and Company 31st Annual Health Care Conference on Monday, March 7, 2011, at 1:45pm ET at the Boston Marriott Copley Place in Boston, Massachusetts. A live webcast of the presentation can be accessed under "Calendar of...

2011-03-01 07:00:00

LYNBROOK, N.Y., March 1, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC; "BioSpecifics"), a biopharmaceutical company developing first in class collagenase-based products, today announced that Pfizer Inc. ("Pfizer") received approval from the European Medicines Agency ("EMA") to market XIAPEX (collagenase clostridium histolyticum) in Europe for the treatment of Dupuytren's contracture, a debilitating disorder resulting from excessive collagen deposition that causes...

2011-02-07 08:35:00

LYNBROOK, N.Y. Feb. 7, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC; the "Company" or "BioSpecifics"), a biopharmaceutical company developing first in class collagenase-based products, today announced that its Board of Directors has amended its Rights Agreement (the "Rights Agreement"), adopted May 14, 2002 and previously amended June 19, 2003 (the "Amendment"). The Amendment increases the ownership threshold for determining "Acquiring Person" status under the Rights...

2011-01-06 16:39:00

LYNBROOK, N.Y., Jan. 6, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC; the "Company" or "BioSpecifics"), a biopharmaceutical company developing first in class collagenase-based products, today announced promising results from its study Chien-802 showing dramatic reductions in canine lipoma following injections with purified injectable collagenase. These results build upon an earlier dose escalation study from which the Company selected the dose for Chien-802. The...